Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
36.72B
Market cap36.72B
Price-Earnings ratio
67.18
Price-Earnings ratio67.18
Dividend yield
Dividend yield
Average volume
1.21M
Average volume1.21M
High today
$283.07
High today$283.07
Low today
$273.11
Low today$273.11
Open price
$279.69
Open price$279.69
Volume
452.79K
Volume452.79K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$273.11
52 Week low$273.11

Stock Snapshot

With a market cap of 36.72B, Alnylam Pharmaceuticals(ALNY) trades at $275.00. The stock has a price-to-earnings ratio of 67.18.

As of 2026-06-18, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $273.11 and $283.07. The current price stands at $275.00, placing the stock +0.7% above today's low and -2.9% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 452.79K, compared to an average daily volume of 1.21M.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $273.11 at its lowest and $495.55 at its peak.

During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $273.11 at its lowest and $495.55 at its peak.

ALNY News

Simply Wall St 2d
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st

...

Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st
TipRanks 3d
Alnylam: Hold Rating Reaffirmed as TTR Franchise Growth Offsets Slight Sales Shortfall; $370 Price Target Unchanged

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma on June 12 and set a price target of $370.00. Claim 55% Off TipRanks Unlock powerf...

Analyst ratings

71%

of 31 ratings
Buy
71%
Hold
29%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.